Med Discovery was founded in 2002 as a spin-off of the Vaudois University Hospital Centre (CHUV) in Lausanne, Switzerland. Med Discovery is an independent company, funded by private investors.
The company evolved out of the research department of the urology department at the CHUV, developing and expanding the focus on onco-urology. The founder group included three biologists and three urologists led by David Deperthes. The breadth of the founders’ backgrounds and experience allows the company to have access to a wide range of competencies. Benefits from this are also seen in the international reach of collaborations, and the well established clinical connections, invaluable to a young biopharmaceutical development company.
By combining biological drug discovery expertise with a strong in-house knowledge of the medical urology field, Med Discovery is uniquely positioned to develop novel drugs for urological cancers and other related solid tumors.